ACAD Live signaler | Maksimer profitt med Getagraph.com

SELG 115473 min ago

@ $25.78

Utstedt: 14 feb 2024 @ 21:32

Avkastning: -33.86%

Forrige signal: feb 14 - 19:10

Forrige signal: Kjøp

Avkastning: 0.72 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	1.12M
Gjennomsnittsvolum	1.81M
Markedsverdi	2.82B
EPS	$0 ( 2024-02-27 )
Neste inntjeningsdato	( $0.170 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-46.08
ATR14	$0.0130 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Schneyer Mark C.	Buy	6 814	Common Stock
2024-05-02	Schneyer Mark C.	Sell	3 503	Common Stock
2024-05-01	Schneyer Mark C.	Sell	6 814	Restricted Stock Units
2024-05-01	Teehan Brendan	Buy	6 814	Common Stock
2024-05-02	Teehan Brendan	Sell	3 477	Common Stock

INSIDER POWER
27.63
Last 98 transactions
Buy: 1 140 321 \| Sell: 756 729

Volum Korrelasjon

Lang: -0.65 (weak negative)

Kort: -0.92 (very strong negative)

Signal:(22.588) Possible Trading Opportunity Present (swing)

ACADIA Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
RRGB	0.956
AUUD	0.944
SVC	0.943
LPSN	0.941
TTEC	0.941
SONN	0.938
BGXX	0.936
RDUS	0.936
BMBL	0.935
AKTS	0.935

10 Mest negative korrelasjoner
TUEM	-0.954
ACGL	-0.946
GRCL	-0.94
RETA	-0.937
LCA	-0.936
USCB	-0.933
GHRS	-0.93
GXII	-0.929
MSDA	-0.928
XLRN	-0.928

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

ACADIA Pharmaceuticals Korrelasjon - Valuta/Råvare

0.55
( weak )

0.53
( weak )

0.00
( neutral )

0.22
( neutral )

0.58
( weak )

ACADIA Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$726.44M
Bruttogevinst:	$680.71M (93.70 %)
EPS:	$-0.370

FY	2023
Omsetning:	$726.44M
Bruttogevinst:	$680.71M (93.70 %)
EPS:	$-0.370

FY	2022
Omsetning:	$517.24M
Bruttogevinst:	$507.07M (98.03 %)
EPS:	$-1.340

FY	2021
Omsetning:	$484.15M
Bruttogevinst:	$465.00M (96.05 %)
EPS:	$-1.067

Financial Reports:

No articles found.

ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Sanntidsoppdatering for ACADIA Pharmaceuticals [ACAD]

Upcoming Earnings Alert